Lv1
16 积分 2022-01-07 加入
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
8小时前
待确认
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
9小时前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
9小时前
已完结
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
9小时前
已完结
Single cell RNA-sequencing reveals molecular signatures that distinguish allergic from irritant contact dermatitis
1个月前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
1个月前
已完结
Integrated single-cell chromatin and transcriptomic analyses of human scalp identify gene-regulatory programs and critical cell types for hair and skin diseases
1个月前
已完结
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
2个月前
已完结
New Investigator Global Assessment Scale in Lichen Planus: OLP IGA
3个月前
已完结
Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome
3个月前
已完结
皖公网安备34019202002308
